Cantor Fitzgerald reiterated their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research report report published on Thursday morning, Benzinga reports. They currently have a $128.00 target price on the biotechnology company’s stock. Other equities analysts also recently issued research reports about the company. Wedbush reissued an outperform rating and […]
Needham & Company LLC restated their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a report published on Thursday morning, Benzinga reports. Needham & Company LLC currently has a $166.00 target price on the biotechnology company’s stock. SRPT has been the topic of several other research reports. TheStreet raised Sarepta Therapeutics […]
Sapient Capital LLC purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,146 shares of the biotechnology company’s stock, valued at approximately $978,000. Several other institutional investors also recently bought […]
Mach 1 Financial Group LLC acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 5,144 shares of the biotechnology company’s stock, valued at approximately $496,000. Several other hedge funds have also […]
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s share price gapped up before the market opened on Thursday following a stronger than expected earnings report. The stock had previously closed at $130.90, but opened at $140.00. Sarepta Therapeutics shares last traded at $136.00, with a volume of 574,101 shares changing hands. The biotechnology company reported […]